<DOC>
	<DOCNO>NCT02691299</DOCNO>
	<brief_summary>Fruquintinib/Placebo 5 mg , QD , orally administer fasting condition 3 consecutive week follow one-week evaluate survival benefit patient advance non-squamous NSCLC treat Fruquintinib .</brief_summary>
	<brief_title>A Phase III Clinical Trial Fruquintinib Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multi-center Phase III clinical trial patient advance non-squamous non-small cell lung cancer ( NSCLC ) treat Fruquintinib fail 2 line systemic chemotherapy non-tolerable toxicity . Approximately 521 subject randomize Fruquintinib group placebo group ratio 2:1 . Patients two group receive supportive treatment . Randomization stratify EGFR gene status ( mutant vs. wild type ) history treatment VEGF inhibitor ( yes v ) . All subject receive study treatment 4-week cycle : Fruquintinib/placebo 3 consecutive week , one week . Tumor assessment perform every 4 week first 2 cycle , every 8 week since 3rd cycle , disease progression death . Subsequent anti-neoplastic treatment survival status follow disease progression .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Fully understand study sign inform consent form voluntarily ; 2 . Histologically cytologically diagnose local advanced and/or metastatic stage IIIB/IV nonsquamous NSCLC ; 3 . Disease progress develop nontolerable toxicity 2 line systemic chemotherapy ( include TKI therapy ) ; Notes : . The firstline chemotherapy platinumbased doublet regimens ; b . For line systemic therapy , least one treatment cycle complete , maintenance therapy use one doublet consider line therapy ; c. Previous adjuvant/neoadjuvant therapy allow . If disease progress adjuvant/neoadjuvant therapy period within 1 year completion treatment , consider patient fail firstline systemic chemotherapy ; 4 . Patients EGFR genetic test negative ; positive EGFR , test result resistant intolerable relate targeted therapy ; 5 . Patients ALK test negative ; positive ALK test result resistant intolerable relate targeted therapy ; 6 . Aged 1875 year ( inclusive ) ; 7 . Measurable disease ( accord RECIST1.1 ) ; 8 . ECOG Performance Status score 01 ; 9 . Life expectancy &gt; 12 week . 1 . Patients participate another clinical trial receive systemic antineoplastic therapy , radiotherapy biotherapy within 3 week prior administration study drug ; receive EGFRTKI treatment past 1 week . 2 . Patients previously receive therapy VEGFR inhibitor ; 3 . Patients recover toxicity cause previous antineoplastic treatment ( CTCAE &gt; grade 1 ) , completely recover previous surgery ; 4 . Patient active brain metastasis ( untreated proper radiation therapy , show clinical symptom symptom stable time le 4 week , indicate symptomatic treatment brain metastasis , etc . ) ; 5 . Patients primary malignancy within past 5 year except basal cell carcinoma skin carcinoma situ cervix ; 6 . Patients uncontrolled active infection , e.g . acute pneumonia , active hepatitis B active hepatitis C , etc . ( patient history hepatitis B , whether treat , HBV DNA ≥500copies ≥ 100IU / ml ) ; 7 . Patients dysphagia know drug malabsorption ; 8 . Patients active duodenal ulcer , ulcerative colitis , intestinal obstruction gastrointestinal disease condition may lead gastrointestinal bleeding perforation accord investigator ' judgment ; history intestinal perforation intestinal fistula ; 9 . Patients fulfil follow criterion shall exclude : 1 ) Absolute neutrophil count ( ANC ) &lt; 1.5×109/L , platelet &lt; 100×109/L hemoglobin &lt; 9 g/dL within 1 week prior enrollment ; 2 ) Serum total bilirubin &gt; 1.5 × upper limit normal ( ULN ) , alanine transaminase aspartate aminotransferase &gt; 2.5×ULN ( accord reference range clinical study site ) ; ALT AST &gt; 5×ULN patient liver metastasis ; 3 ) Clinically significant electrolyte abnormality ; 4 ) Blood creatinine &gt; ULN creatinine clearance &lt; 60 ml/min ; 5 ) Urine protein 2+ , urine protein quantification ≥1.0 g/24 h ; 6 ) Activated partial thromboplastin time ( APTT ) or/and INR prothrombin time ( PT ) &gt; 1.5×ULN ( accord reference range clinical study site ) ; 10 . Patients uncontrolled hypertension , systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg symptomatic treatment ; 11 . Patients leave ventricular ejection fraction &lt; 50 % ( echocardiography ) heart function evaluation ; 12 . Patients acute myocardial infarction , severe/unstable angina coronary bypass surgery within 6 month prior enrollment ; cardiac insufficiency NYHA II ; 13 . Patients history arterial thrombosis deep venous thrombosis within 6 month prior enrollment , history evidence thrombosis bleeding tendency regardless severity within 2 month prior enrollment ; history hemoptysis ( i.e . cough blood bright red color least 1/2 teaspoon ) within 2 week prior enrollment ; 14 . Patients history stroke and/or transient ischemic attack within 12 month prior enrollment ; 15 . Patients skin wound , surgical site , wound site , severe mucosal ulcer fracture without complete healing ; 16 . Pregnant lactate woman , woman child bear potential positive pregnancy test result first dose ; 17 . Patients child bear potential whose sexual partner willing take contraceptive measure ; 18 . Patients clinical laboratory abnormality unsuitable participate clinical trial accord investigator 's judgment ; 19 . Patients serious psychological psychiatric disorder may affect subject compliance clinical study ; 20 . Patients allergic analogue Fruquintinib and/or inactive ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
</DOC>